IPSEN S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.38 USD | -0.26% |
|
+2.38% | +3.05% |
| Jul. 11 | CAC40: maintains gains after reassuring US inflation figures | CF |
| Jul. 11 | CAC40: rise without volume, W-Street at its zenith but falls back | CF |
| Sales 2024 * | 3.46B 3.78B | Sales 2025 * | 3.69B 4.04B | Capitalization | 9.19B 10.04B |
|---|---|---|---|---|---|
| Net income 2024 * | 637M 696M | Net income 2025 * | 709M 775M | EV / Sales 2024 * | 2.52 x |
| Net cash position 2024 * | 483M 528M | Net cash position 2025 * | 1.14B 1.25B | EV / Sales 2025 * | 2.18 x |
| P/E ratio 2024 * |
14.5
x | P/E ratio 2025 * |
13.1
x | Employees | 5,325 |
| Yield 2024 * |
1.1% | Yield 2025 * |
1.09% | Free-Float | 41.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipsen S.A.
More press releases
More news
| 1 day | -0.26% | ||
| 1 week | +2.38% | ||
| Current month | +0.73% | ||
| 1 month | -7.91% | ||
| 3 months | +6.14% | ||
| 6 months | +5.96% | ||
| Current year | +3.05% |
1 week
29.55
30.50
1 month
28.5831.05
Current year
27.0034.06
1 year
26.9734.34
3 years
21.1734.34
5 years
9.1034.34
10 years
9.1044.60
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 55 | 14-11-02 | |
| Chairman | 66 | 10-11-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 67 | 17-06-06 |
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 66 | 15-05-26 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-17 | 30.38 | -0.26% | 552 |
| 24-07-16 | 30.46 | +3.08% | 891 |
| 24-07-15 | 29.55 | -0.42% | 942 |
| 24-07-10 | 29.68 | +3.83% | 494 |
| 24-07-09 | 28.58 | -4.96% | 316 |
Delayed Quote OTC Markets, July 17, 2024 at 02:41 pm EDT
More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-07-23
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
111.2
EUR
Average target price
127.3
EUR
Spread / Average Target
+14.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.35% | 815B | |
| +32.43% | 597B | |
| -0.10% | 377B | |
| +15.47% | 319B | |
| +13.10% | 310B | |
| +16.26% | 247B | |
| +14.45% | 228B | |
| +16.54% | 180B | |
| +4.31% | 170B |
- Stock Market
- Equities
- IPN Stock
- IPSEY Stock
